- Conditions
- Leukemia, Acute Myeloid Leukemia, AML
- Interventions
- Cytarabine, Idarubicin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 906
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Peripheral Blood Stem Cell, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor, Total-Body Irradiation
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- inotuzumab ozogamicin, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 96
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 39 more
- Conditions
- Diffuse Large Cell Lymphoma Relapsed/Refractory
- Interventions
- Ofatumumab, Etoposide, Cytarabine
- Drug
- Lead sponsor
- C. Babis Andreadis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytarabine consolidation, Allogeneic transplant
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Azacitidine, Sargramostim
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Cytosine Arabinoside
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 55 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Sertraline, Cytosine arabinoside, allogeneic stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Lymphoma, Hodgkin's Disease
- Interventions
- Melphalan, Ara-C, VP-16, BCNU, Rituxan, Stem Cells
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2017
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Leukemia
- Interventions
- cytarabine, gemtuzumab ozogamicin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 151
- States / cities
- Berkeley, California • Burlingame, California • Greenbrae, California + 95 more
- Conditions
- Multiple Myeloma
- Interventions
- Interim/Maintenance Dexamethasone, Induction/Consolidation Dexamethasone, Induction/Consolidation Cisplatin, Induction/Consolidation Adriamycin, InductionConsolidation Cyclophosphamide, Induction/Consolidation Etoposide, Induction Pegfilgrastim, Transplant 1 Dexamethasone, Transplant 1 Cisplatin, Transplant 1 Adriamycin, Transplant 1 Cyclophosphamide, Transplant 1 Etoposide, Transplant 1 Melphalan, Transplant 1 and 2 Pegfilgrastim, Autologous Peripheral Blood Stem Cell Transplant (ASCT), Transplant 2 Carmustine, Transplant 2 Etoposide, Transplant 2 Cytarabine, Transplant 2 Melphalan, Transplant 2 Dexamethasone, Transplant 1 and 2 Bortezomib, Transplant 1 and 2 Thalidomide
- Drug · Procedure
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- ALRN-6924, ALRN-6924 in combination with cytarabine
- Drug
- Lead sponsor
- Aileron Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Denver, Colorado • Tampa, Florida • The Bronx, New York + 3 more
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Interventions
- Laromustine (VNP40101M) and Ara-C
- Drug
- Lead sponsor
- Viron Therapeutics Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Interventions
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, AML, Childhood
- Interventions
- Cytarabine, Daunorubicin, Erwinase, Etoposide, Gemtuzumab ozogamicin, Stem cell transplantation (SCT), Sorafenib
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Leukemia
- Interventions
- Clofarabine, Idarubicin, Cytarabine, Fludarabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 366 Days to 46 Years
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more
- Conditions
- Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma
- Interventions
- dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone, allogeneic hematopoietic stem cell transplantation, CliniMACS
- Drug · Biological · Other + 2 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 3
- States / cities
- San Diego, California • Memphis, Tennessee • Fort Worth, Texas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Venetoclax, Azacitidine, Cytarabine, Gemtuzumab Ozogamicin, Daunorubicin Hydrochloride, Fludarabine Phosphate, Idarubicin Hydrochloride, Mitoxantrone Hydrochloride, Etoposide, Gilteritinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 29 Days to 21 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 10
- States / cities
- Madera, California • Orange, California • San Diego, California + 7 more
- Conditions
- Newly Diagnosed AML With FLT3 Activating Mutations
- Interventions
- crenolanib, cytarabine, daunorubicin, idarubicin
- Drug
- Lead sponsor
- Arog Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Duarte, California • Iowa City, Iowa • Boston, Massachusetts + 5 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Vosaroxin and Cytarabine
- Drug
- Lead sponsor
- Hamid Sayar
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
- Interventions
- Cytarabine, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, G-CSF mobilized peripheral blood cells
- Drug · Other · Procedure + 1 more
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Up to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Drug · Procedure
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 4
- States / cities
- Columbus, Ohio • Houston, Texas • Seattle, Washington